Literature DB >> 12448688

Sulphated and sulphonated polymers inhibit the initial interaction of hepatitis B virus with hepatocytes.

C Ying1, J F Van Pelt, A Van Lommel, M Van Ranst, P Leyssen, E De Clercq, J Neyts.   

Abstract

The initial step during hepatitis B virus (HBV) infection is the specific attachment of the virus to the hepatocyte. Here we studied whether the binding of HBV to hepatocytes can, as is the case with most other enveloped viruses, be blocked by polyanionic compounds. Viral particles produced by HepAD38 cells were used as inoculum and HBV-negative HepG2 cells, as well as primary human hepatocytes, as target cells. Three sulphated polymers, that is, PAVAS (a co-polymer of acrylic acid with vinyl alcohol sulphate), heparin and dextran sulphate (DS) (MW 5000), and the sulphonated polymer PAMPS [poly(2-acryl-amido-2-methyl-1-propanesulfonic acid] (MW approximately 7000-12000), proved strong inhibitors of the binding of HBV to HepG2 cells and primary hepatocytes. The 50% effective concentration (EC50) for inhibition of HBV binding to HepG2 cells by PAVAS, heparin, DS and PAMPS was 1.3 microg/ml, 1.6 microg/ml, 1.8 microg/ml and 3.3 microg/ml, respectively, and to primary hepatocytes 1.6 microg/ml (PAVAS), 1.6 microg/ml (heparin), 2.6 microg/ml (DS) and 4.1 microg/ml (PAMPS). These values are in the same range as the concentrations required for these compounds to prevent such viruses as herpesviruses and HIV from binding to cells. These findings may be helpful in elucidating the mechanism of the initial interaction of HBV with hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12448688     DOI: 10.1177/095632020201300302

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  9 in total

Review 1.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

2.  Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells.

Authors:  Tamara Severi; Chunxiao Ying; Joris Robert Vermeesch; David Cassiman; Lieselotte Cnops; Chris Verslype; Johan Fevery; Lutgarde Arckens; Johan Neyts; Jos F van Pelt
Journal:  Mol Cell Biochem       Date:  2006-09-08       Impact factor: 3.396

Review 3.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 4.  Hepatitis B: Current Status of Therapy and Future Therapies.

Authors:  Elias Spyrou; Coleman I Smith; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2020-03-29       Impact factor: 3.806

5.  Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus.

Authors:  Manujendra N Saha; Atsushi Tanaka; Atsushi Jinno-Oue; Nobuaki Shimizu; Kazushi Tamura; Masahiko Shinagawa; Joe Chiba; Hiroo Hoshino
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Feasibility of Repurposing the Polyanionic Microbicide, PPCM, for Prophylaxis against HIV Transmission during ART.

Authors:  Robert A Anderson; David Brown; Erin M Jackson; Kenneth A Feathergill; James W Bremer; Ralph Morack; Richard G Rawlins
Journal:  ISRN Obstet Gynecol       Date:  2010-11-28

Review 7.  Hepatitis B Virus Entry into Cells.

Authors:  Charline Herrscher; Philippe Roingeard; Emmanuelle Blanchard
Journal:  Cells       Date:  2020-06-18       Impact factor: 6.600

8.  A Novel Sulfonated Derivative of β-Cyclodextrin Effectively Inhibits Influenza A Virus Infection in vitro and in vivo.

Authors:  E P Goncharova; Y A Kostyro; A V Ivanov; M A Zenkova
Journal:  Acta Naturae       Date:  2019 Jul-Sep       Impact factor: 1.845

Review 9.  Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis.

Authors:  Chiara Urbinati; Paola Chiodelli; Marco Rusnati
Journal:  Molecules       Date:  2008-11-06       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.